New Articles of Association


Company Announcement no. 10/2013

  

To: NASDAQ OMX Copenhagen A/S                                                        Hørsholm, Denmark, 1 May 2013

 

New Articles of Association

 

Hørsholm, 1 May 2013 – Veloxis Pharmaceuticals A/S (OMX: VELO), has today registered revised articles of association with the Danish Business Authority in continuation of the company's annual general meeting held on 17 April 2013.

The new articles of association is attached.

 

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino                                                 Johnny Stilou

President & CEO                                        EVP, Chief Financial Officer

Mobile: +1 917 647 9107                          Mobile: +45 21 227 227

Email: wjp@veloxis.com                           Email: jst@veloxis.com

  

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

 


Attachments

170413 Articles of Association.pdf 010513 Veloxis Announces Articles of Association.pdf